Physician profile
Daniel D Cabello
NPI 1730196965
$79,152.38
in general payments reported to CMS, 2019-2025
71 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,563 · 2021: $6,411 · 2022: $19K · 2023: $11K · 2024: $6,146 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Honoraria: $11K · Travel and Lodging: $1,090 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,751.11 |
| Honoraria | $11,300.00 |
| Travel and Lodging | $1,090.34 |
| Education | $320.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $29,414.61 | 2020-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $19,429.48 | 2019-2022 | |
| Ucb, INC. | $7,406.34 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Abbvie INC. | $2,790.52 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Jazz Pharmaceuticals INC. | $1,933.01 | 2019-2025 | Epidiolex |
| Eisai INC. | $1,424.84 | 2019-2025 | |
| Lundbeck LLC | $1,096.95 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $1,084.44 | 2023-2025 | |
| Allergan, INC. | $969.12 | 2019-2022 | |
| Lilly USA, LLC | $946.19 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $855.54 | 2019-2025 | Nuplazid, Daybue |
| Harmony Biosciences LLC | $846.10 | 2020-2025 | Wakix |
| Amgen INC. | $717.88 | 2019-2024 | Aimovig |
| Neurocrine Biosciences, INC. | $679.38 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $656.05 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cabello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.